首页> 外文OA文献 >Modeling Imaginary Worlds: Version 4 of the AMCP Format for Formulary Submissions
【2h】

Modeling Imaginary Worlds: Version 4 of the AMCP Format for Formulary Submissions

机译:模拟虚幻世界:建议性提交的AMCP格式的版本4

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The question of demarcation between normal science and pseudoscience is critical to the discovery of new facts. The core elements supporting progress in science are: (i) empirically evaluable coherent theories and (ii) the testing of hypotheses through experimentation or systematic observation. If modeled or simulation-based claims for cost-effectiveness are to be accepted as a credible input to health care decision making than they must conform to these standards. Claims should be testable, falsifiable and replicable. If not then they are best seen as pseudoscience. This assessment of the latest version of the Academy of Managed Care Pharmacy (AMCP) Format for Formulary Submissions (Version 4.0; April 2016) concludes that, in their recommendations for cost-effectiveness modeling, the proposed standards do not meet those of normal science. Rather, in common with previous versions of the AMCP Format, the modeling framework proposed not only puts to one side the issue of testable claims, but supports the modeling of imaginary worlds or thought experiments where claims are immune to falsification. In consequence, the payer or other recipient of a modeled or simulated claim that follows the AMCP Format has no idea, in the absence of observation or experimentation, whether the claim is right or even if it is wrong. The claims are potentially misleading, possibly harmful, but to an unknown extent. They have no place in evidence-based medicine.Conflict of InterestNoneType: Commentary
机译:正常科学与伪科学之间的划分问题对于发现新事实至关重要。支持科学进展的核心要素是:(i)经验可评估的相干理论和(ii)通过实验或系统观察测试假设。如果要接受基于建模或模拟的成本效益的索赔,则被认为是对医疗保健决策的可信输入,而不是必须符合这些标准。索赔应该是可测试的,劣质和可复制的。如果不是,那么它们最好被视为伪科学。本评估了最新版本的托管护理药学学院(AMCP)格式的形式(版本4.0; 2016年4月)的结论是,在他们对成本效益建模的建议中,拟议的标准不符合正常科学的标准。相反,与以前版本的AMCP格式共同,建议的建模框架不仅被施加到了可测试的索赔问题,而且支持假想世界或思想实验的建模,其中索赔免受伪造的影响。因此,在没有观察或实验的情况下,在没有观察或实验的情况下,应当或其他索赔的付款人或其他接收者在没有观察或实验的情况下,索赔是否是正确的甚至是错误的。索赔可能误导,可能有害,但在未知程度上。他们没有循证医学的地方。利益冲突没有任何类型:评论

著录项

  • 作者

    Paul C Langley;

  • 作者单位
  • 年度 2016
  • 总页数
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号